Literature DB >> 31822527

Tubular Acidification Defect in Adults with Sickle Cell Disease.

Maud Cazenave1, Vincent Audard2, Jean-Philippe Bertocchio3, Anoosha Habibi4, Stéphanie Baron3, Caroline Prot-Bertoye3, Jugurtha Berkenou4, Gérard Maruani5, Thomas Stehlé2, Nicolas Cornière6, Hamza Ayari3, Gérard Friedlander5, Frédéric Galacteros4, Pascal Houillier3, Pablo Bartolucci4, Marie Courbebaisse7.   

Abstract

BACKGROUND AND OBJECTIVES: Metabolic acidosis is a frequent manifestation of sickle cell disease but the mechanisms and determinants of this disorder are unknown. Our aim was to characterize urinary acidification capacity in adults with sickle cell disease and to identify potential factors associated with decreased capacity to acidify urine. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 25 adults with sickle cell disease and an eGFR of ≥60 ml/min per 1.73 m2 from a single center in France, we performed an acute acidification test after simultaneous administration of furosemide and fludrocortisone. A normal response was defined as a decrease in urinary pH <5.3 and an increase in urinary ammonium excretion ≥33 µEq/min at one or more of the six time points after furosemide and fludrocortisone administration.
RESULTS: Of the participants (median [interquartile range] age of 36 [24-43] years old, 17 women), 12 had a normal and 13 had an abnormal response to the test. Among these 13 participants, nine had normal baseline plasma bicarbonate concentration. Plasma aldosterone was within the normal range for all 13 participants with an abnormal response, making the diagnosis of type 4 tubular acidosis unlikely. The participants with an abnormal response to the test were significantly older, more frequently treated with oral bicarbonate, had a higher plasma uric acid concentration, higher hemolysis activity, lower eGFR, lower baseline plasma bicarbonate concentration, higher urine pH, lower urine ammonium ion excretion, and lower fasting urine osmolality than those with a normal response. Considering both groups, the maximum urinary ammonium ion excretion was positively correlated with fasting urine osmolality (r 2=0.34, P=0.002), suggesting that participants with sickle cell disease and lower urine concentration capacity have lower urine acidification capacity.
CONCLUSIONS: Among adults with sickle cell disease, impaired urinary acidification capacity attributable to distal tubular dysfunction is common and associated with the severity of hyposthenuria. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_12_10_CJN07830719.mp3.
Copyright © 2020 by the American Society of Nephrology.

Entities:  

Keywords:  France; acidosis; adult; ammonium compounds; body fluids; epidermal growth factor receptor; fasting urine osmolality; fludrocortisone; furosemide; glomerular filtration rate; homeostasis; human EGFR protein; metabolic acidosis; renal insufficiency; sickle cell anemia; sickle cell disease; urinary tract

Mesh:

Substances:

Year:  2019        PMID: 31822527      PMCID: PMC6946065          DOI: 10.2215/CJN.07830719

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  31 in total

1.  Prevalence and correlates of metabolic acidosis among patients with homozygous sickle cell disease.

Authors:  Stéphane Maurel; Katia Stankovic Stojanovic; Virginie Avellino; Alexey Girshovich; Emmanuel Letavernier; Gilles Grateau; Laurent Baud; Robert Girot; Francois Lionnet; Jean-Philippe Haymann
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-23       Impact factor: 8.237

2.  Intravascular hemolysis activates complement via cell-free heme and heme-loaded microvesicles.

Authors:  Nicolas S Merle; Anne Grunenwald; Helena Rajaratnam; Viviane Gnemmi; Marie Frimat; Marie-Lucile Figueres; Samantha Knockaert; Sanah Bouzekri; Dominique Charue; Remi Noe; Tania Robe-Rybkine; Marie Le-Hoang; Nathan Brinkman; Thomas Gentinetta; Monika Edler; Sara Petrillo; Emanuela Tolosano; Sylvia Miescher; Sylvain Le Jeune; Pascal Houillier; Sophie Chauvet; Marion Rabant; Jordan D Dimitrov; Veronique Fremeaux-Bacchi; Olivier P Blanc-Brude; Lubka T Roumenina
Journal:  JCI Insight       Date:  2018-06-21

3.  Magnetic Resonance Imaging Assessment of Kidney Oxygenation and Perfusion During Sickle Cell Vaso-occlusive Crises.

Authors:  Jean-François Deux; Vincent Audard; Pierre Brugières; Anoosha Habibi; Elena-Maria Manea; Constance Guillaud-Danis; Bertrand Godeau; Frédéric Galactéros; Thomas Stehlé; Philippe Lang; Philippe Grimbert; Etienne Audureau; Alain Rahmouni; Pablo Bartolucci
Journal:  Am J Kidney Dis       Date:  2016-09-20       Impact factor: 8.860

4.  Erythrocyte density in sickle cell syndromes is associated with specific clinical manifestations and hemolysis.

Authors:  Pablo Bartolucci; Carlo Brugnara; Armando Teixeira-Pinto; Serge Pissard; Kamran Moradkhani; Hélène Jouault; Frederic Galacteros
Journal:  Blood       Date:  2012-08-23       Impact factor: 22.113

5.  Re-Evaluation of the Normal Range of Serum Total CO2 Concentration.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Clin J Am Soc Nephrol       Date:  2018-01-16       Impact factor: 8.237

6.  Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density.

Authors:  H A Deutschmann; M Weger; W Weger; P Kotanko; M J Deutschmann; F Skrabal
Journal:  J Intern Med       Date:  2002-11       Impact factor: 8.989

7.  Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride.

Authors:  S B Walsh; D G Shirley; O M Wrong; R J Unwin
Journal:  Kidney Int       Date:  2007-04-04       Impact factor: 10.612

8.  Six Months of Hydroxyurea Reduces Albuminuria in Patients with Sickle Cell Disease.

Authors:  Pablo Bartolucci; Anoosha Habibi; Thomas Stehlé; Gaetana Di Liberto; Marie Georgine Rakotoson; Justine Gellen-Dautremer; Sylvain Loric; Stéphane Moutereau; Dil Sahali; Orianne Wagner-Ballon; Philippe Remy; Philippe Lang; Philippe Grimbert; Etienne Audureau; Bertrand Godeau; Frédéric Galacteros; Vincent Audard
Journal:  J Am Soc Nephrol       Date:  2015-11-19       Impact factor: 10.121

9.  Dense red blood cell and oxygen desaturation in sickle-cell disease.

Authors:  Gaetana Di Liberto; Laurent Kiger; Michael C Marden; Laurent Boyer; Florence Canoui Poitrine; Marc Conti; Marie Georgine Rakotoson; Anoosha Habibi; Sanam Khorgami; Benoit Vingert; Bernard Maitre; Frederic Galacteros; France Pirenne; Pablo Bartolucci
Journal:  Am J Hematol       Date:  2016-08-04       Impact factor: 10.047

10.  Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

Authors:  Mark T Gladwin; Vandana Sachdev; Maria L Jison; Yukitaka Shizukuda; Jonathan F Plehn; Karin Minter; Bernice Brown; Wynona A Coles; James S Nichols; Inez Ernst; Lori A Hunter; William C Blackwelder; Alan N Schechter; Griffin P Rodgers; Oswaldo Castro; Frederick P Ognibene
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245

View more
  5 in total

1.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

2.  Hyperkalemia and Metabolic Acidosis Occur at a Higher eGFR in Sickle Cell Disease.

Authors:  Santosh L Saraf; Vimal K Derebail; Xu Zhang; Roberto F Machado; Victor R Gordeuk; James P Lash; Jane Little
Journal:  Kidney360       Date:  2022-02-03

Review 3.  The nephropathy of sickle cell trait and sickle cell disease.

Authors:  Kenneth I Ataga; Santosh L Saraf; Vimal K Derebail
Journal:  Nat Rev Nephrol       Date:  2022-02-21       Impact factor: 42.439

Review 4.  Advances in the diagnosis and treatment of sickle cell disease.

Authors:  A M Brandow; R I Liem
Journal:  J Hematol Oncol       Date:  2022-03-03       Impact factor: 17.388

5.  Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition.

Authors:  Pamela L Brito; Alisson F Dos Santos; Hanan Chweih; Maria E Favero; Erica M F Gotardo; Juliete A F Silva; Flavia C Leonardo; Carla F Franco-Penteado; Mariana G de Oliveira; Wilson A Ferreira; Bruna C Zaidan; Athanase Billis; Giorgio Baldanzi; Denise A Mashima; Edson Antunes; Sara T Olalla Saad; Fernando F Costa; Nicola Conran
Journal:  PLoS One       Date:  2022-02-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.